1. Home
  2. UTSI vs QNCX Comparison

UTSI vs QNCX Comparison

Compare UTSI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UTStarcom Holdings Corp.

UTSI

UTStarcom Holdings Corp.

HOLD

Current Price

$2.95

Market Cap

22.9M

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$0.91

Market Cap

19.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTSI
QNCX
Founded
1991
2012
Country
China
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9M
19.9M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
UTSI
QNCX
Price
$2.95
$0.91
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
4.9K
1.4M
Earning Date
03-24-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.88
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.34
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.08
52 Week High
$2.94
$4.55

Technical Indicators

Market Signals
Indicator
UTSI
QNCX
Relative Strength Index (RSI) 64.09 38.84
Support Level $2.34 $0.79
Resistance Level N/A $0.98
Average True Range (ATR) 0.10 0.09
MACD 0.01 -0.03
Stochastic Oscillator 94.12 0.56

Price Performance

Historical Comparison
UTSI
QNCX

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Share on Social Networks: